Plum Creek Care Center | |
1505 North Adams Street, Lexington, Nebraska 68850 | |
(308) 324-5531 | |
Name | Plum Creek Care Center |
---|---|
Location | 1505 North Adams Street, Lexington, Nebraska |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 66 |
Occupancy Rate | 43.94% |
Medicare ID (CCN) | 285159 |
Legal Business Name | Kismet Lxn Llc |
Ownership Type | For Profit - Corporation |
NPI Number | 1972504207 |
Organization Name | KISMET LXN, LLC. |
Doing Business As | PLUM CREEK CARE CENTER |
Address | 1505 N Adams St, Lexington, NE 68850 |
Phone Number | 308-324-5531 |
News Archive
Apollo Life Sciences, a Sydney-based biotechnology company, has announced that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies.
Against the backdrop of last week's Congressional hearing into the future of forensic science, researchers from the University at Buffalo's Laboratory for Forensic Odontology Research in the School of Dental Medicine, have published a landmark paper on the controversial topic of bitemark analysis.
Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
The American Association of Critical-Care Nurses will present the ICU Design Citation to the newborn and infant critical care unit (NICCU) at Children's Hospital Los Angeles during the 2014 National Teaching Institute & Critical Care Exposition, Denver, May 17-22.
› Verified 5 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Apollo Life Sciences, a Sydney-based biotechnology company, has announced that its topical psoriasis treatment has outperformed current market-leading drugs in preclinical studies.
Against the backdrop of last week's Congressional hearing into the future of forensic science, researchers from the University at Buffalo's Laboratory for Forensic Odontology Research in the School of Dental Medicine, have published a landmark paper on the controversial topic of bitemark analysis.
Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies, and asthmatic reactions without suppressing a sufferer's entire immunological system.
Arisaph Pharmaceuticals, Inc., a privately held drug discovery biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted the Company's recently submitted Investigational New Drug application to evaluate ARI-3037MO in a phase I human clinical trial in healthy volunteers.
The American Association of Critical-Care Nurses will present the ICU Design Citation to the newborn and infant critical care unit (NICCU) at Children's Hospital Los Angeles during the 2014 National Teaching Institute & Critical Care Exposition, Denver, May 17-22.
› Verified 5 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 2 |
Total Amount of Fines in Dollars | $16250 |
Number of Payment Denials | 0 |
Total Number of Penalties | 2 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 8.04 | 14.46 |
Percentage of long-stay residents who lose too much weight | 8.18 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 53.66 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.6 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 1.77 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 10.28 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 7.76 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 88.79 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 17.76 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 52.78 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 5 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 44.35 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.78 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 11.93 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.62 | 95.98 |